Japan CRISPR-Cas9 Gene Editing Market to Reach US$856.4 Million by 2033 | Growth in Pharma & Biotechnology Insights, Funding & Industry Developments (2026)

DataM Intelligence has published a new research report on "Japan CRISPR-Cas9 Gene Editing Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Download Free Sample PDF Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/japan-crispr-cas9-gene-editing-market?kb

Japan: Recent Industry Developments 2026:

✅ February 2026: C4U Corporation secured up to USD 14 million (JPY 2 billion) in non-dilutive funding from the Japan Agency for Medical Research and Development to advance CRISPR-based hematopoietic stem cell therapy for primary immunodeficiency.

✅ January 2026: Takeda Pharmaceutical partnered with a domestic biotech startup to develop CRISPR-Cas9 gene-editing therapeutics targeting rare genetic disorders.

✅ December 2025: Kyoto University researchers reported successful in vitro correction of a rare liver disorder using CRISPR-Cas9, moving toward preclinical trials.

✅ December 2025: Fujifilm Cellular Dynamics initiated development of CRISPR-edited iPSC lines for regenerative medicine applications.

✅ December 2025: Ongoing government-backed initiatives continue to support infrastructure for CRISPR-based R&D, focusing on regulatory alignment and clinical trial acceleration.

Strategic Acquisitions 2026:

ERS Genomics & Japanese partner licensing

✦ ERS Genomics Ltd (holders of foundational CRISPR‐Cas9 IP co‐owned by Dr. Emmanuelle Charpentier) signed a non‐exclusive commercialization agreement with Fasmac Co., Ltd of Japan.

✦ Under this deal, Fasmac gains rights to use and commercialize CRISPR‐Cas9 tools in Japan, potentially expanding local availability of reagents and CRISPR‐based kits.

✦ Financial terms were not disclosed - these licensing deals are often structured with upfront fees plus royalties rather than outright acquisitions.

Kyoto University iPS Genome Editing Resource

✦ Kyoto University iPS Cell Research Foundation launched a clinical‐grade HLA genome‐edited iPS cell stock using CRISPR‐Cas9 (targeting HLA genes), making resources available to industry and academia.

✦ This enhances Japan's research backbone, a key enabler for biotech collaborations/M&A or biotech startup spin‐outs.

Regen Med Start‐ups & Engagements

✦ Programs like the Japan Entry Acceleration Program (JEAP) attracted overseas regenerative medicine and gene‐therapy startups to pitch to Japanese companies, potentially opening avenues for future collaboration, co‐development, and acquisition interest in gene editing technologies.

Top 10 Japanese Key Players 2026:

1. Takeda Pharmaceutical Company Limited
2. DAIICHI SANKYO COMPANY, LIMITED
3. Thermo Fisher Scientific Inc.
4. Merck KGaA
5. Takara Bio Inc.
6. DH Life Sciences, LLC.
7. GenScript
8. Sumitomo Chemical Co., Ltd.
9. Astellas Pharma Inc.
10. Illumina, Inc.

Key Developments 2026:

In June 2025, C4U Corporation received up to USD 14 million (JPY 2 billion) in non-dilutive funding from the Japan Agency for Medical Research and Development to advance its CRISPR-based stem cell therapy for primary immunodeficiency, supporting clinical validation and safety assessments. This move underscores Japan's growing government-backed investment in the CRISPR-Cas9 gene editing ecosystem

✅ February 2026: Leading biotech firms in Japan expanded clinical research on CRISPR-Cas9 therapies targeting rare genetic disorders, enhancing precision gene-editing efficiency and reducing off-target effects.

✅ January 2026: Collaborative projects between universities and pharmaceutical companies accelerated development of CRISPR-based immunotherapies, leveraging AI-driven gene targeting and predictive modeling.

✅ December 2025: Agricultural biotech startups increased deployment of CRISPR-Cas9 for crop improvement, focusing on disease resistance, yield enhancement, and climate adaptability.

✅ November 2025: Regulatory agencies in Japan streamlined approvals for early-stage CRISPR clinical trials, promoting faster translation of lab research into therapeutic applications.

✅ October 2025: Research institutions adopted automated CRISPR-Cas9 platforms to scale high-throughput gene-editing experiments and improve reproducibility.

✅ August 2025: Investment in CRISPR startups surged as venture capital and government funding targeted precision medicine, regenerative therapies, and biopharmaceutical innovations.

✅ June 2025: Public-private partnerships facilitated knowledge sharing and ethical guidelines development, supporting responsible CRISPR-Cas9 research and clinical adoption.

Growth Forecast Projection 2026:

The Japan CRISPR-Cas9 Gene Editing Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Funding by Companies Accelerates CRISPR-Cas9 Innovation in Japan

✅ The Japan CRISPR-Cas9 gene editing market is seeing strong government and corporate-backed funding aimed at advancing next-generation therapies and accelerating clinical applications. In 2025-2026, several key developments highlight growing investment momentum:

✅ C4U Corporation secured up to USD 14 million (JPY 2 billion) in non-dilutive funding from the Japan Agency for Medical Research and Development (AMED) under the Strengthening Program for Pharmaceutical Startup Ecosystem, supporting its CRISPR-based hematopoietic stem cell therapy for primary immunodeficiency.

✅ Pharmaceutical and biotechnology companies continue to attract venture and grant funding to accelerate gene editing therapies targeting oncology, rare diseases, and regenerative medicine.

✅ Government-backed initiatives in Japan are providing structured funding programs to facilitate clinical validation, safety assessments, and translational research, reinforcing the country's position as a hub for genome editing innovation.

✅ Corporate collaborations between startups and established pharma are increasingly leveraging combined financial and R&D resources to scale CRISPR-based therapeutic development and expedite commercialization.

Research Process 2026:

Both primary and secondary data sources have been used in the Japan CRISPR-Cas9 Gene Editing Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=japan-crispr-cas9-gene-editing-market?kb

Key Segments 2026:

pharmaceutical and biotechnology companies dominated the Japan CRISPR-Cas9 gene editing market, accounting for the largest revenue share of 46.6% in 2025

• By Product - CRISPR Cas9 reagents including enzymes, guide RNAs, vectors, kits, and instruments drive research and clinical applications.

• By Technology - CRISPR Cas9 nuclease editing, CRISPRi, CRISPRa, and base editing enable precise gene modification and therapy development.

• By End User - Pharmaceutical & biotechnology companies, academic institutes, CROs, hospitals, and agricultural biotech firms are the primary adopters.

Benefits of the Report:

Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.

Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.

Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.

Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.

Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.

Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.

Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.

Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.

Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/japan-crispr-cas9-gene-editing-market?kb

FAQ

Q1: What is the current size of the Japan CRISPR-Cas9 Gene Editing Market?

A: The Japan CRISPR-Cas9 Gene Editing Market was valued at US$232.3 Million in 2024, Value Cross to US$268.5 Million in 2025 and is forecasted to reach US$856.4 Million by 2033

Q2: How rapidly will the Market expand?

A: The Japan CRISPR-Cas9 Gene Editing market is projected to grow at a CAGR of 15.6% between 2026 and 2033.

Contact Us For Custom Research: https://www.datamintelligence.com/custom-research?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.